Statements (58)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:activities |
inhibits complement activation
|
| gptkbp:appointed_by |
intravenous infusion
|
| gptkbp:approves |
gptkb:2007
gptkb:FDA |
| gptkbp:availability |
prescription only
|
| gptkbp:class |
gptkb:drug
|
| gptkbp:clinical_trial |
gptkb:Ultomiris
Phase III chronic treatment |
| gptkbp:contraindication |
hypersensitivity to eculizumab
|
| gptkbp:developed_by |
gptkb:Alexion_Pharmaceuticals
|
| gptkbp:dosage_form |
solution for infusion
|
| gptkbp:education |
importance of vaccination
recognizing infection symptoms |
| gptkbp:formulation |
sterile liquid
|
| https://www.w3.org/2000/01/rdf-schema#label |
Eculizumab
|
| gptkbp:indication |
complement-mediated disorders
|
| gptkbp:ingredients |
C_6076 H_9312 N_1620 O_1870 S_44
|
| gptkbp:interacts_with |
live vaccines contraindicated
immunosuppressants caution |
| gptkbp:invention |
gptkb:2020
|
| gptkbp:is_monitored_by |
complete blood count
infection signs |
| gptkbp:is_used_for |
treatment of paroxysmal nocturnal hemoglobinuria
treatment of atypical hemolytic uremic syndrome treatment of generalized myasthenia gravis |
| gptkbp:manager |
IV
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:Japan gptkb:United_States |
| gptkbp:pharmacokinetics |
complement inhibition
long half-life |
| gptkbp:population |
gptkb:Person
adults |
| gptkbp:price |
high cost
|
| gptkbp:provides_information_on |
included in treatment guidelines
|
| gptkbp:research |
post-marketing studies
ongoing clinical trials |
| gptkbp:research_areas |
neurology
autoimmune diseases hematology nephrology |
| gptkbp:safety_features |
required for long-term use
|
| gptkbp:sales |
in billions
|
| gptkbp:side_effect |
fatigue
headache nausea diarrhea increased risk of infections infusion reactions serious infections improves quality of life in patients |
| gptkbp:targets |
complement protein C5
|
| gptkbp:traded_on |
gptkb:Soliris
|
| gptkbp:weight |
148,000 Da
|
| gptkbp:bfsParent |
gptkb:Mitsubishi_Tanabe_Pharma
|
| gptkbp:bfsLayer |
4
|